Medtech research spending set to slow in 2022
And some diagnostics groups are forecast to actually cut R&D outlay this year as the pandemic eases.
Biotech smells the coffee
A couple of small M&A deals this week shows more developers capitulating to the new reality.
To buy or build blockbusters?
A look at blockbuster origins shows the role of external innovation, but more of these huge franchises are in the hands of their inventors than ever before.
PTC’s confirmatory Duchenne data resurrect US hopes
Real-world data on Translarna look good, but with a failed confirmatory trial and a troubled history US approval is far from guaranteed.
Up-and-down test sales and a bigger Medtronic: medtech in 2028
Medtronic, Siemens and Stryker are all expected to seize greater market share, while Roche slides down the rankings.
Roche deal fails to Repare the licensing scene
Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.
